How GLP-1 Medications Affect Mental Health: Patients Share Their Experiences
Patients on GLP-1 drugs reported complex mental health effects — improvements from weight loss coexisted with challenges from side effects and changed eating habits.
Quick Facts
What This Study Found
Patients experienced both mental health improvements (from weight loss and metabolic gains) and challenges (from side effects and disrupted eating patterns) on GLP-1 medications.
Key Numbers
9 participants interviewed at 12-16 weeks after GLP-1 RA initiation. Three main themes identified through reflexive thematic analysis.
How They Did This
Qualitative study using semi-structured interviews with 9 participants, analyzed via reflexive thematic analysis.
Why This Research Matters
Clinical trials focus on physical outcomes, but patients' lived mental health experiences with GLP-1 drugs are equally important for treatment decisions.
The Bigger Picture
This qualitative evidence fills a gap in understanding the psychological dimension of GLP-1 treatment, which large trials often overlook.
What This Study Doesn't Tell Us
Small qualitative sample (9 participants) — captures depth but not breadth. Self-selection bias possible.
Questions This Raises
- ?Do mental health effects differ between specific GLP-1 medications?
- ?How do psychological experiences evolve beyond 16 weeks of treatment?
Trust & Context
- Key Stat:
- 3 themes Acceptance of negatives, changed food relationships, and mixed mood effects emerged from patient interviews
- Evidence Grade:
- Qualitative research — provides rich experiential data but cannot be generalized. Valuable for understanding patient perspectives.
- Study Age:
- Published in 2025, capturing contemporary patient experiences with current GLP-1 medications.
- Original Title:
- A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists.
- Published In:
- Acta diabetologica, 62(5), 731-742 (2025)
- Database ID:
- RPEP-13052
Evidence Hierarchy
Uses interviews or focus groups to understand experiences in depth.
What do these levels mean? →Frequently Asked Questions
Do GLP-1 drugs affect mental health?
Patients report mixed effects — improvements from weight loss and health gains coexist with challenges from side effects and changes in their relationship with food.
Should I expect mood changes on GLP-1 medication?
Some patients experience shifts in mood and eating psychology. Discussing these possibilities with your doctor before starting can help you prepare.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13052APA
Pierret, Aureliane C S; Benton, Madeleine; Sen Gupta, Piya; Ismail, Khalida. (2025). A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists.. Acta diabetologica, 62(5), 731-742. https://doi.org/10.1007/s00592-024-02392-0
MLA
Pierret, Aureliane C S, et al. "A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists.." Acta diabetologica, 2025. https://doi.org/10.1007/s00592-024-02392-0
RethinkPeptides
RethinkPeptides Research Database. "A qualitative study of the mental health outcomes in people ..." RPEP-13052. Retrieved from https://rethinkpeptides.com/research/pierret-2025-a-qualitative-study-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.